Department of Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia; Department of Anaesthesia, Austin Health, Melbourne, VIC, Australia.
Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia; Methods and Implementation Support for Clinical and Health research Hub, The University of Melbourne, Melbourne, VIC, Australia.
Lancet Haematol. 2022 Jul;9(7):e514-e522. doi: 10.1016/S2352-3026(22)00142-9.
One in two adults undergoing cardiac surgery are iron deficient, best practice guidelines and consensus statements recommend routine investigation and treatment of iron deficiency before elective cardiac surgery, even in the absence of anaemia; however, it is not clear if non-anaemic iron deficiency is associated with worse outcomes in this patient population. We hypothesised that iron deficiency would be associated with worse postoperative outcomes than an iron replete state in adults without anaemia undergoing elective cardiac surgery.
We performed a prospective, cohort study at two hospitals in Australia. We recruited adults (ie, people 18 years and older) undergoing elective cardiac surgery without anaemia (defined as a haemoglobin of less than 130 g/L for men and less than 120 g/L for women), concomitant haemoglobinopathy, bone marrow pathology, haemochromatosis, or end-stage renal failure requiring dialysis. Participants were stratified as iron deficient or iron replete on the basis of preoperative testing. Iron deficiency was defined as a serum ferritin of less than 100 μg/L or 100-300 μg/L if transferrin saturation was less than 20% or C-reactive protein was more than 5 mg/L. The primary endpoint was days alive and at home at postoperative day 30. The primary analysis included all patients with data available for the primary endpoint and was adjusted for risk measured using EuroSCORE-II and body surface area. The study was prospectively registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12618000185268.
We conducted the study between Feb 21, 2018, and May 7, 2021. We assessed 1171 patients for eligibility and 691 were ineligible; therefore, we enrolled and followed up 480 participants. 240 (50%) were iron deficient and 240 (50%) were iron replete, 95 (20%) were women, 385 (80%) were men, and 453 (94%) were White. Complete data was available for 479 individuals (240 in the iron deficient group and 239 in the iron replete group) for the primary endpoint. The iron deficient group had a median of 22·87 days (IQR 20·65 to 24·06) alive and at home at postoperative day 30, and the iron replete group had a median of 23·18 days (IQR 20·69 to 24·70). The unadjusted difference in medians between the groups was -0·18 days (95% CI -0·73 to 0·36; p=0·51) and the adjusted difference in medians between the groups was -0·11 days (95% CI -0·66 to 0·45; p=0·70).
In non-anaemic adults undergoing elective cardiac surgery, our findings suggest that patients with iron deficiency do not have a reduction in days alive and at home at postoperative day 30 compared with patients who have a normal iron status. Routine preoperative investigation for iron deficiency in patients without anaemia undergoing elective cardiac surgery using the definitions we tested might be low-value care.
Australian and New Zealand College of Anaesthetists Foundation.
在接受心脏手术的成年人中,有二分之一存在铁缺乏,最佳实践指南和共识声明建议在择期心脏手术前常规检查和治疗铁缺乏,即使没有贫血;然而,在这一患者人群中,非贫血性铁缺乏是否与更差的术后结局相关尚不清楚。我们假设,与铁充足状态相比,非贫血性铁缺乏与接受择期心脏手术的无贫血成年人的术后结局更差。
我们在澳大利亚的两家医院进行了一项前瞻性队列研究。我们招募了接受择期心脏手术的成年人(即年龄在 18 岁及以上),这些人没有贫血(定义为男性血红蛋白低于 130 g/L,女性血红蛋白低于 120 g/L),同时没有合并血红蛋白病、骨髓病理学、血色病或需要透析的终末期肾病。根据术前检查,参与者被分为铁缺乏或铁充足。铁缺乏定义为血清铁蛋白<100 μg/L 或 100-300 μg/L,如果转铁蛋白饱和度<20%或 C 反应蛋白>5 mg/L。主要终点是术后第 30 天存活且在家的天数。主要分析包括所有主要终点数据可用的患者,并根据使用 EuroSCORE-II 和体表面积测量的风险进行调整。该研究在澳大利亚和新西兰临床试验注册处进行了前瞻性注册,ACTRN12618000185268。
我们于 2018 年 2 月 21 日至 2021 年 5 月 7 日开展了这项研究。我们评估了 1171 名患者的入选资格,其中 691 名不符合入选条件;因此,我们招募并随访了 480 名参与者。240 名(50%)存在铁缺乏,240 名(50%)铁充足,95 名(20%)为女性,385 名(80%)为男性,453 名(94%)为白人。对于主要终点,有 479 名个体(铁缺乏组 240 名,铁充足组 239 名)的数据完整。铁缺乏组在术后第 30 天存活且在家的中位数为 22.87 天(IQR 20.65-24.06),铁充足组为 23.18 天(IQR 20.69-24.70)。两组间中位数的未调整差异为-0.18 天(95%CI-0.73 至 0.36;p=0.51),两组间中位数的调整差异为-0.11 天(95%CI-0.66 至 0.45;p=0.70)。
在接受择期心脏手术的非贫血成年人中,我们的研究结果表明,与铁状态正常的患者相比,铁缺乏的患者在术后第 30 天存活且在家的天数并没有减少。在接受择期心脏手术且没有贫血的患者中,使用我们测试的定义进行常规术前铁缺乏检查可能是低价值的。
澳大利亚和新西兰麻醉师学院基金会。